

CURRICULUM VITAE

Prof. Dr. Bernd Hoppe

Current positions

- 04/2020-ongoing Kindernierenzentrum Bonn, Pediatric Nephrology and Head of German Hyperoxaluria Center, Bonn, Germany
- 12/2019-ongoing Consultant the Wisplinghoff Labs, Hyperoxaluria and Stone lab, Cologne, Germany

Previous affiliations

- 07/2019-05/2022 Head, Global Medical Affairs, Dicerna Pharmaceuticals, Lexington, USA

Previous positions and Specialization in Pediatrics and in Pediatric Nephrology:

- 09/2012-06/2019 Attending Physician, Professor of Pediatrics, Head, Division of Pediatric Nephrology, University Hospital Bonn, Germany
- 1998-09/2012: Senior Registrar and since 1999 Attending Physician, Professor of Pediatrics, Head, Division of Pediatric Nephrology, University of Cologne, Germany
- 1996 – 1998: Basic research on oxalate metabolism, Northwestern University, Children's Memorial Hospital, Division of Nephrology, Chicago, IL, USA.
- 1993 - 1996: University Children's Hospital Cologne, Germany;
- 1993: Hannover Medical School, Department of Pediatrics, Division of Pediatric Nephrology, Hannover, Germany;
- 1991 - 1992: University Children's Hospital Zurich, Switzerland; Research fellow, Division of Pediatric Nephrology;
- 1990: Pediatric Surgery, Children's Hospital St. Marien, Landshut-Munich, Germany;

- 1988 - 1990: Children's Hospital St. Augustin, Teaching Hospital University of Bonn, Germany;

Periods of elective study and clinical attachments:

- 1988: Surgery, Flinders University of South Australia, Adelaide, Australia.
- 1988: Pediatrics, University Children's Hospital Zurich, Switzerland;
- 1987/88: Internal Medicine, University Hospital Zurich, Switzerland;
- 1986: Paediatric Surgery, Children's Hospital St. Marien, Landshut/ Munich, Germany;
- 1986: Internal Medicine, Regional Hospital Glarus, Switzerland;

MD-Thesis (1990):

Alkaline-citrate metaphylaxis in patients with recurrent calcium-oxalate urolithiasis.

Professorship (1999):

New approaches in diagnosis, treatment and follow up in primary hyperoxaluria type 1

Memberships:

- German Society of Pediatrics
- German Society of Pediatric Nephrology
- German Society of Nephrology
- European Society for Pediatric Nephrology
- International Pediatric Nephrology Association
- American Society of Nephrology

Board specified in:

- Pediatrics
- Pediatric Nephrology

GCP Training:

- 11.-13.3.2009, Principal Investigator Training, Clinical Trials Center of Düsseldorf/Cologne, in Düsseldorf, Germany
- 19.3.2014 Clinical Trials Course update, IZKS Mainz
- 9.3.2016 GCP Update course, ZKS Bonn
- 27.9.2017 GCP Refresher, ZKS Bonn
- 5.05.2020 online GCP Refresher
- GCP Basisschulung 29.12.2022
- 11.1.2023 online GCP Aufbauschulung

Selected research Support

Industry support, ongoing

- Systemic oxalosis in the primary hyperoxalurias
- Pharmacotherapy in the primary hyperoxaluria
- Oxalate spikes and renal outcome
- Glyoxalate determination

Deutsche Forschungsgemeinschaft, SFB TRR 2016-2020

Trautwein, Kurts, et al. Organ Fibrosis: From Mechanisms of Injury to Modulation of Disease

German Israeli Foundation I-328-201.3-2012: 2013-2016

Frishberg, Belostotsky, Beck, Hoppe and Reintjes, Translation inhibition of mutant alanine glyoxylate aminotransferase - a novel therapeutic modality for primary hyperoxaluria type I

FP7-SME-2013 Research for the benefit of SMEs

Biopharmaceutical therapy for treatment of Primary Hyperoxaluria (ELIMOX), Oxthera AB and partners, UK Bonn (Hoppe), Uni Lyon (Cochat), UCLH NHS (Hulton)

German Research Foundation (DFG) Ho 1272/21-1

Feldkötter, Hoppe and co-workers, 2011-2016, DiaSport – Endurance-orientated training program for children and adolescents on maintenance hemodialysis to enhance dialysis efficacy

Cologne, Faculty program University of Cologne Medical Center

Hoppe and Hoyer 2010-2011. Vitamin B6 treatment in primary hyperoxaluria, a systemic evaluation

Selected recent papers

- Bernd Hoppe, Cristina Martin-Higuera, Lodovica Borghese, Sophie Kaspar, Björn Reusch, Bodo B. Beck, Adam Walli, Ella Janzen, Sebastian Hegert, Nils Janzen, Katharina Hohenfellner. Effective newborn screening for type 1 and 3 primary hyperoxaluria. *Kidney Int Rep.* 2024; <https://doi.org/10.1016/j.ekir.2024.10.006>
- Cristina Martin-Higuera, Lodovica Borghese, Armando Torres, Malte P. Bartram, Bodo B. Beck...and Bernd Hoppe. Multicenter Long-Term Real World Data on Treatment With Lumasiran in Patients With Primary Hyperoxaluria Type 1. *Open AccessPublished:October 06, 2023 DOI:<https://doi.org/10.1016/j.ekir.2023.10.004>*
- Vali PS, Hoppe B. Is Genotype the Major Outcome Parameter of Kidney Failure in Patients With Primary Hyperoxaluria Type 1? *Kidney Int Rep.* 2023 Sep 7;8(11):2187-2190. doi: 10.1016/j.ekir.2023.09.012. PMID: 38025235; PMCID: PMC10658403.
- Merz LM, Born M, Kukuk G, Sprinkart AM, Becker I, Martin-Higuera C, Hoppe B. Three Tesla magnetic resonance imaging detects oxalate osteopathy in patients with primary hyperoxaluria type I. *Pediatr Nephrol.* 2022 Dec 6. doi: 10.1007/s00467-022-05836-3. Epub ahead of print. Erratum in: *Pediatr Nephrol.* 2023 Jan 11;; PMID: 36472654.
- Michelle A. Baum, Craig Langman, Pierre Cochat, John C. Lieske, Shabbir H. Moochhala, Shuzo Hamamoto, Hiroyuki Satoh, Chebl Mourani, Gema Ariceta, Armando Torres, Martin Wolley, Vladimir Belostotsky, Thomas A. Forbes, Jaap Groothoff, Wesley Hayes, Burkhard Tönshoff, Tatsuya Takayama, Ralf Roskamp, Kerry Russell, Jing Zhou, Aniruddha Amrite, Bernd Hoppe. PHYOX2: A Pivotal Randomized Study of Nedosiran in Primary Hyperoxaluria Type 1 or 2, *Kidney Int.* 2022 Aug 22:S0085-2538(22)00631-7. doi:10.1016/j.kint.2022.07.025. Epub ahead of print. PMID: 36007597.
- Hoppe B, Koch A, Cochat P, Garrelfs SF, Baum MA, Groothoff JW, Lipkin G, Coenen M, Schalk G, Amrite A, McDougall D, Barrios K, Langman CB. Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria. *Kidney Int.* 2022 Mar;101(3):626-634. doi: 10.1016/j.kint.2021.08.015. Epub 2021 Sep 2. PMID: 34481803.
- Hoppe B, Martin-Higuera C. Improving Treatment Options for Primary Hyperoxaluria. *Drugs.* 2022 Jul;82(10):1077-1094. doi: 10.1007/s40265-022-01735-x. Epub 2022 Jul 2. PMID: 35779234; PMCID: PMC9329168.
- Martin-Higuera C, Garrelfs SF, Groothoff JW, Jacob DE, Moochhala SH, Bacchetta J, Acquaviva C, Zaniew M, Sikora P, Beck BB, Hoppe B. A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3. *Kidney Int.* 2021 Sep;100(3):621-635. doi: 10.1016/j.kint.2021.03.031. Epub 2021 Apr 16. PMID: 33865885.
- Hillebrand P, Hoppe B. Plasma oxalate levels in primary hyperoxaluria type I show significant intra-individual variation and do not correlate with kidney

function. *Pediatr Nephrol.* 2020 Jul;35(7):1227-1233. doi: 10.1007/s00467-020-04531-5. Epub 2020 Apr 9. PMID: 32274573.

Bonn, November 25th 2024

A handwritten signature in black ink, consisting of a large, stylized 'B' followed by a horizontal line and a small flourish.

Bernd Hoppe, MD